Ligand Pharmaceuticals | LGND - Ebit


Ligand Pharmaceuticals reported $54.53M in EBIT for its fiscal quarter ending in September of 2026.





Ebit Change Date
Agenus USD 15.05M 656K Mar/2026
Amgen USD 4.68B 65M Sep/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -154.34M 13.08M Jun/2026
Baxter International USD 314M 38M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Eli Lilly USD 13.09B 635M Sep/2026
Enanta Pharmaceuticals USD -23.54M 6.31M Dec/2024
Enviri Corporation USD -35.28M 61.58M Dec/2025
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
Glaxosmithkline GBP 2.15B 157M Sep/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -81.83M 19.48M Sep/2026
Intrexon USD -26.3M 2.91M Jun/2024
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Ligand Pharmaceuticals USD 54.53M 2.1M Sep/2026
MacroGenics USD -65.25M 33.36M Jun/2026
Merck USD 7.33B 6.49B Sep/2026
Pacira USD 2.57B 2.56B Sep/2026
Pfizer USD 4.85B 5.03B Sep/2026
Rigel Pharmaceuticals USD 447K 1.52M Jun/2024
Veracyte USD 18.02M 5.94M Sep/2026